Literature DB >> 2473465

Synthesis of gelatin microspheres containing interferon.

Y Tabata1, Y Ikada.   

Abstract

Gelatin microspheres with a diameter less than 2 microns were synthesized by means of cross-linking with glutaraldehyde. When the microspheres were subjected to degradation in phosphate-buffered saline solution containing collagenase, the digestion of microspheres was found to decrease with increasing cross-linking. Interferon was incorporated in the microspheres at a high trapping efficiency, and the rate of interferon release from the microspheres was regulated by the extent of cross-linking with glutaraldehyde. Gelatin microspheres incorporating interferon-alpha were readily phagocytosed by macrophages, regardless of the extent of cross-linking, and the phagocytosed microspheres were observed to be degraded gradually in the interior of macrophages, resulting in the slow release of the incorporated interferon in the cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473465     DOI: 10.1023/a:1015991617704

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  A new oral gelatinized sustained-release dosage form.

Authors:  N TANAKA; S TAKINO; I UTSUMI
Journal:  J Pharm Sci       Date:  1963-07       Impact factor: 3.534

2.  An application of water-in-oil and gelatin-microsphere-in-oil emulsions to specific delivery of anticancer agent into stomach lymphatics.

Authors:  M Hashida; Y Takahashi; S Muranishi; H Sezaki
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

3.  Role of intramuscular administration of water-in-oil emulsions as a method for increasing the delivery of anticancer agents to regional lymphatics.

Authors:  M Hashida; M Egawa; S Muranishi; H Sezaki
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

4.  Microencapsulation of a waxy solid: wall thickness and surface appearance studies.

Authors:  P L Madan; L A Luzzi; J C Price
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

5.  Protein measurement by ninhydrin determination of amino acids released by alkaline hydrolysis.

Authors:  R McGrath
Journal:  Anal Biochem       Date:  1972-09       Impact factor: 3.365

6.  The dissociation of the attachment and ingestion phases of phagocytosis by macrophages.

Authors:  M Rabinovitch
Journal:  Exp Cell Res       Date:  1967-04       Impact factor: 3.905

Review 7.  Methods to quantify endocytosis: a review.

Authors:  R I Kavet; J D Brain
Journal:  J Reticuloendothel Soc       Date:  1980-02

8.  Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors.

Authors:  T Kataoka; N Matsuura; F Oh-hashi; Y Suhara
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

9.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.

Authors:  T Barlozzari; J Leonhardt; R H Wiltrout; R B Herberman; C W Reynolds
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

10.  Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres.

Authors:  Y Tabata; Y Ikada
Journal:  J Pharm Pharmacol       Date:  1987-09       Impact factor: 3.765

View more
  13 in total

1.  Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole.

Authors:  E E Hassan; R C Parish; J M Gallo
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

2.  Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit.

Authors:  Yu Ma; Yi Wan; Dong-Hui Luo; Li-Geng Duan; Lin Li; Chuan-Qin Xia; Xiao-Li Chen
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

3.  An in situ cross-linking hybrid hydrogel for controlled release of proteins.

Authors:  Hila Epstein-Barash; Cristina F Stefanescu; Daniel S Kohane
Journal:  Acta Biomater       Date:  2012-02-08       Impact factor: 8.947

4.  Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model.

Authors:  A Nitta-Seko; N Nitta; A Sonoda; H Otani; K Tsuchiya; S Ohta; M Takahashi; K Murata
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

5.  A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model.

Authors:  N Nitta; A Sonoda; A Seko; S Ohta; Y Nagatani; K Tsuchiya; H Otani; T Tanaka; S Kanasaki; M Takahashi; K Murata
Journal:  Br J Radiol       Date:  2009-12-17       Impact factor: 3.039

6.  Preparation and evaluation of danofloxacin mesylate microspheres and its pharmacokinetics in pigs.

Authors:  Chunmei Wang; Diyun Ai; Cuilan Chen; Heng Lin; Jing Li; Hongchun Shen; Weixue Yi; Yuanhua Qi; Haigang Wu; Jiyue Cao
Journal:  Vet Res Commun       Date:  2009-09-23       Impact factor: 2.459

7.  In vivo investigation of ceftiofur-loaded gelatin and PLGA microspheres in beagle dogs.

Authors:  Zhihui Hao; Leilei Wang; Kefeng Xiao; Yongda Zhao; Ming Zou; Qidi Zhang; Zhaopeng Ding; Fenfang Yang; Baohan Qu
Journal:  J Mater Sci Mater Med       Date:  2013-01-26       Impact factor: 3.896

8.  Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization.

Authors:  Yue Wei Zhang; Jin Ao; Ying Liu; Ming Xi Qiao; Xue Ling Yang; Shun Xiong Tang; Chuang Li; Ke Xu
Journal:  Tumour Biol       Date:  2014-08-02

9.  Vascular regeneration by pinpoint delivery of growth factors using a microcatheter reservoir system in a rabbit hind-limb ischemia model.

Authors:  Norihisa Nitta; Ayumi Nitta-Seko; Akinaga Sonoda; Shobu Watanabe; Keiko Tsuchiya; Kiyoshi Murata; Yasuhiko Tabata
Journal:  Exp Ther Med       Date:  2012-05-11       Impact factor: 2.447

10.  131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment.

Authors:  Yu Ma; Ligeng Duan; Lin Li; Wusheng Lu; Bo Li; Xiaoli Chen
Journal:  J Gastrointest Oncol       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.